Overview

Ixabepilone Administered as an Enteric Coated Formulation.

Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the pharmacokinetics of oral Ixabepilone.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
R-Pharm
Treatments:
Epothilones